This big one in Wuhan, one "ashore" a year

Optics Valley Biological City has set up a fund for a fund for a company company in 5 years.

In 5 years, the Optics Valley Biological City adds a new listed company each year. Correspondent Guyu Photo Conferry

"Two companies are now reviewing on the exchange, and 3 companies are doing listing counseling." In 5 years, Optics Valley Biological City will add one new company every year, and 39 provincial -level listed "gold seeds" enterprises are going to go to On the way to the market. At present, a group of enterprises in the Optics Valley Biological City are on the market and move forward.

01

The development of the development of Wuhan Technology's self -reliance is strong

From scratch, from small to large, from large to strong, to listed from the Optics Valley Biological City Enterprise Group, you can see the development of Wuhan's self -reliance.

The biological industry is related to life and health, and is the most patient industry. From "seeds" incubation, flowering, and fruiting to the market, it is inseparable from government guidance and cultivation.

"At that time, there were very few funds in Wuhan's local biomedicine." The relevant person in charge of the Optics Valley Biological City introduced that in order to improve the docking efficiency of the biological city enterprises and capital, the Optics Valley Biological City has established a "biological innovation" service platform. The company's capital market cultivation and investment and financing roadshow are connected. At present, the 207th issue has been held normalized.

The listing effect of Optics Valley Biological Enterprises has attracted a number of capital cultivation. Correspondent Guyu Photo Conferry

In recent years, the listing effect of Optics Valley Biological Enterprises has attracted a number of capital cultivation. At the end of last year, Wuhan Weiko Medical completed Sequoia China to invest hundreds of millions of yuan B financing. Sequoia Chinese partner Ms. Yang Yunxia said that the significance of atrial shunting in the company's atrioventricular treatment is being accepted by more and more experts worldwide. Surgery is also a product suitable for the characteristics of epidemiological epidemiological diseases in China. Only Ke is one of the pioneers in these fields.

Three months ago, Heyuan Bio completed a 556 million yuan Pre-IPO round of financing, and the GEM listed company Beida Pharmaceutical Co., Ltd. and its affiliated parties led. Dr. Ding Liechi, chairman and CEO of Beida Pharmaceuticals, said that the plant source of Heyuan Bio has a reorganized human serum albumin injection. , It can fill the blank of reorganization of human serum protein. Very optimistic about the company's technical platform, and is confident in its long -term development.

Almost synchronized with He Yuan Bio, Binhui Bio completed nearly 300 million yuan B+financing in April this year, led by Yangzijiang Pharmaceutical Group.

Recently, Wuhan Youzhi Youbi Biopharmaceutical Co., Ltd. has received 200 million yuan of investment from 3 Guanggu State -owned SASAC.

In 2021, almost half of the financing of Optics Valley companies in the first -level market came from the field of biomedicine.

02

Small and medium -sized enterprises co -construction bases with the Stock Exchange will continue listing

Four years ago, under the active sighter of Optics Valley Biological City, the Provincial Government Finance Office coordinated and coordinated. The Optics Valley Biological City and the Shanghai Stock Exchange signed a contract to jointly build the Shanghai Stock Exchange Capital Market to serve the Hubei Base. The Shenzhen Stock Exchange Hubei Capital Market Cultivation Base has established a smooth communication channel with the exchange.

In 2018, Mingde Biological Login of the Shenzhen Stock Exchange was a small and medium -sized board; in 2019, Jiabiyou landed in the science and technology board; the pre -science and technology board of the science and technology board in 2020; the main board of the Hong Kong Stock Exchange in the Hong Kong Stock Exchange in 2021; in 2022 Huayang Medical Logging in the GEM ... … Behind listing continues is more than 10 years of self -relocation of Wuhan science and technology enterprises, and the attractiveness of capital has been continuously enhanced.

03

Listed companies have fund feeding industrial chains to become bigger and stronger

After the enterprise was listed, the funds in their hands were relatively abundant. Through the acquisition of the connection to the chain, the main enterprise of the main enterprise was enlarged and strengthening the chain, and the effect of multi -level capital market linkage helped the innovation and development of the industry.

Not long ago, Mingde Biological and Junlian Capital invested 165 million yuan to set up funds, focusing on projects in the fields of innovative diagnosis and treatment technology based on molecular biology. Twelve years ago, the Optics Valley Biological City Enterprise Mingde Biosaidon received the investment of the Angels of Junlian Capital; 12 years later, the listed company Mingde Biological Lianjun Capital, a listed company of the leading enterprises in the field, accelerated the strong industrial chain.

Two months ago, Kang Sheng Global Corporation invested the fund with a subscription amount of $ 12.5 million, mainly investing in high -growth innovative medical health and life science companies.

"Nine % of Optics Valley Biological City is a small and medium -sized enterprise engaged in the development of original biomedical technology." The relevant person in charge of the Optics Valley Biological City introduced that the field of biomedicine, from technology mature to product listing, short -term, three or five years, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten long, ten, ten, ten, ten, ten, ten, ten, ten, ten, ten, ten, ten, ten, ten, ten, ten, ten, ten, ten, ten, ten, ten, ten, ten, ten, ten, ten, ten, and ten. For a few twenty years, during this period, the company had no sales income. If there was no capital injection, it would be easy to die halfway. From the beginning of the establishment of the Optics Valley Biological City, it has begun to build a multi -level financial service system. From the four boards, three boards to the motherboard, accompanied by the way, helping enterprises regulate management, organize production and finance docking meetings, help enterprises do capital, and accompany them for more than ten years. Run, watching the company grows up and goes on the market. "The fundamental to the industry is in the enterprise, creating an industrial cluster with global influence. There must be a group of listed companies with global industrial influence."

The Optics Valley Biomedical Biomedical Enterprise continued to be listed, and it became a film, indicating that the industrial structure of Wuhan had undergone qualitative changes. Conversely, changes in the industrial structure will further promote the butterfly changes in the Wuhan biomedical industry.

Not long ago, Optics Valley released the "Several Policies on Promoting the Development of the Innovation Pharmaceutical Industry". The country's first "New Medicine Creation Partner" model is planned. By 2030, the total output value of innovative drug companies exceeds 100 billion yuan, and 20 innovative drug companiesLog in to the mainstream capital market, and 30 new drugs were approved for listing.Changjiang Daily reporter He Liang Correspondent Su Cheng Sudan

Edit Ye Tuoli

Source Yangtze River Daily Wuhan released

- END -